Clinical updates, including trial initiations, enrollment status and data readouts and publications: ADC, Afimmune, Aztherapies, Bexion, Biolinerx, Biontech, Bioversys, Boehringer, Chiasma, Cogent, Enlivex, Genoscience, Gilead, Greenwich, Helixmith, Hepion, Kazia, Lilly, Milestone, Moderna, Neurosense, Oncosec, Organicell, Pfizer, Pionyr, Puretech, Sanofi, Sernova, VBI.

Shares of Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) fell 66.3% to $4.02 on Nov. 17 following news that its autologous cell therapy candidate, Nurown, missed the primary efficacy endpoint of a phase III amyotrophic lateral sclerosis (ALS) study.

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Aivita, Ampio, Avrobio, Bayer, Beigene, Brainstorm, Cerebral, Cymabay, Dicerna, Eicosis, Eiger, Galderma, Jupiter, Kangpu, Kiniksa, Lexicon, Mydecine, Novo, Palladio, Poxel, PTC, Rigel, Trippbio, Urogen.

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Adverum, Akebia, Alligator, Aptevo, Atara, Beyondspring, Bioaegis, Biological E., Calypso, Cerevance, Dynavax, Genenta, Intravacc, Karyopharm, Kodiak, Moderna, Medexus, Obseva, Precigen, PTC, Rapt, Redhill, Revelation, Rhovac.

DUBLIN – The contest to bring a safe and effective gene therapy for X-linked retinitis pigmentosa (XLRP) to market is intensifying. Two of the three contenders with clinical-stage programs reported initial 12-month data from phase I/II trials and are now looking ahead to pivotal trials and beyond.

Clinical updates, including trial initiations, enrollment status and data readouts and publications: 89 Bio, Akero, Albireo, Alnylam, Amarin Annexon, Arrowhead, Biocryst, Bridgebio, Durect, Esperion, Gemini, Greenwich, Horizon, Incarda, Ionis, Mirum, Myokardia, Navidea, Neurorx, NGM, Nkarta, Novartis, Surface, Takeda, VBI.